Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class IgM Based Bispecific Antibody Igm-2323 (anti-CD20 x anti-CD3) in Patients with Advanced B-Cell Malignancies

62nd American Society of Hematology (ASH) Annual Meeting and Exposition, December 5-8, 2020
Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies
Number: 1142, December 5, 2020

Elizabeth Budde, MD, PhD, et al.
Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation
City of Hope National Medical Center

ASH 2020 IGM-2323 Poster Abstract #1142

Posted in publications.